Related Experiment Videos
Biologic markers in borderline personality disorder: a review
H W Lahmeyer1, C F Reynolds, D J Kupfer
1Department of Psychiatry, University of Illinois, Chicago 60680.
The Journal of Clinical Psychiatry
|June 1, 1989
Summary
Biologic markers show potential for diagnosing co-occurring depression in borderline personality disorder (BPD) patients. EEG sleep and other markers may help differentiate diagnoses, guiding targeted BPD treatment.
Area of Science:
- Psychiatry
- Neuroscience
- Genetics
Background:
- Borderline personality disorder (BPD) frequently co-occurs with other psychiatric diagnoses, notably depression.
- Accurate diagnosis of comorbid conditions is crucial for effective treatment of BPD patients.
Purpose of the Study:
- To review the utility of biologic markers in evaluating BPD patients.
- To explore the potential of specific biomarkers in differentiating Axis I codiagnoses, particularly depression, in BPD.
Main Methods:
- Review of existing literature on biologic markers in BPD.
- Analysis of studies examining EEG sleep patterns, monoamine oxidase, red blood cell lithium ratio, and P300 auditory evoked potentials.
- Evaluation of pharmacologic trial outcomes in BPD patients.
Main Results:
- Biologic markers have not proven effective for diagnosing BPD itself.
- Electroencephalogram (EEG) sleep abnormalities are observed in BPD and can help distinguish depression from other Axis I codiagnoses.
- Monoamine oxidase, red blood cell lithium ratio, and P300 auditory evoked potentials show promise in identifying codiagnoses.
- Dexamethasone suppression and thyrotropin-releasing hormone tests appear nonspecific for this population.
- Pharmacologic trials indicate that some BPD patients respond well to antipsychotics and tranylcypromine, but poorly to alprazolam.
Conclusions:
- Specific biologic markers, such as EEG sleep, may aid in identifying comorbid depression in BPD patients.
- Certain biomarkers hold promise for improving diagnostic accuracy of codiagnoses in BPD.
- Treatment response varies, with some BPD patients benefiting from antipsychotics and tranylcypromine, suggesting distinct pathophysiological pathways.